Amgen, Inc.’s newly-approved interchangeable biosimilar to Johnson & Johnson’s anti-inflammatory drug Stelara will face challenges in generating solid returns in the Medicare Part D program because the innovator's price could be substantially reduced by the government in 2026, one year after the biosimilar’s expected January 2025 launch.
Amgen Biosimilar For Stelara May Face Price Drop In Medicare Shortly After Launch; What’s A Follow-On To Do?
With J&J's Stelara set for Medicare negotiation, the fate of Amgen’s new ustekinumab interchangeable be a test case for concerns that the pricing program will significantly undercut incentives for developing biosimilars for blockbusters in the Medicare market.
More from Market Access
More from Pink Sheet
• By
Pink Sheet reporter and editors discuss how staff may not be the only thing the FDA could lose with the latest layoffs announced by the Health and Human Services Department.
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.